替罗非班对高危非致残性缺血性进展性卒中患者神经功能的影响  

Effect of Tirofiban on Neurological Function in Patients with High-risk Non-disabling Ischemic Progressive Stroke

作　　者：刘深龙 辛立建 马媛媛 杨辉 LIU Shen-long;XIN Li-jian;MA Yuan-yuan;YANG Hui(Department of Neurology, Cangzhou People's Hospital, Cangzhou, Hebei Province, 061000 China;Department of Neurology, Renqiu Second Peopled Hospital, Renqiu, Hebei Province, 062550 China)

机构地区：[1]沧州市人民医院神经内科 [2]任丘市第二人民医院神经内科

出　　处：《系统医学》2019年第14期82-84,共3页Systems Medicine

基　　金：沧州市科学技术局课题项目,课题名称：替罗非班对高危非致残性缺血性进展性卒中患者的应用研究(172302010)

摘　　要：目的探讨替罗非班对高危非致残性缺血性进展性卒中患者神经功能的影响。方法选该院100例2017年4月-2018年6月高危非致残性缺血性进展性卒中患者。随机数字表分组,对照组实施常规药物治疗,观察组则实施常规药物加上替罗非班治疗。比较对照组、观察组疗效;患者神经功能缺损评分降低50%的时间、住院时间;治疗前后患者神经功能缺损评分评估情况、生存质量情况;不良反应。结果观察组疗效98.00%高于对照组78.00%(χ^2=8.013,P<0.05);观察组患者神经功能缺损评分降低50%的时间、住院时间(6.11±1.41)d、(10.13±0.24)d更好(t=8.291、9.152,P<0.05);治疗后观察组神经功能缺损评分评估情况、生存质量情况(11.56±3.21)分、(93.19±4.35)分优于对照组(t=6.934、5.812,P<0.05)。观察组不良反应8.00%和对照组10.00%差异无统计学意义(χ^2=0.644,P>0.05)。结论常规药物加上替罗非班治疗高危非致残性缺血性进展性卒中的效果理想。Objective To investigate the neurological function of tirofiban in patients with high-risk non-disabling ischemic progressive stroke.Methods A total of 100 patients with high-risk non-disabling ischemic progressive stroke from April 2017 to June 2018 were enrolled in our hospital.The random number table was grouped,the control group was treated with conventional drugs,and the observation group was treated with conventional drugs and tirofiban.The efficacy of the control group and the observation group were compared;the time of the neurological deficit score was reduced by 50%,the length of hospital stay;the evaluation of neurological deficit scores before and after treatment,and the quality of life;adverse reactions were compared.Results The efficacy of the observation group was 98.00% higher than that of the control group(78.00%)(χ^2=8.013,P<0.05).The time of the neurological deficit score decreased by 50%in the observation group,and the hospitalization time was(6.11±1.41)d and(10.13±0.24)d,respectively(t=8.291,9.152,P<0.05).The evaluation of neurological deficit score and quality of life in the observation group after treatment were 11.56±3.21)points and(93.19±4.35)points,which were better than the control group(t=6.934,5.812,P<0.05).There was no statistically significant difference between the 8.00% of the adverse reactions in the observation group and 10.00% in the control group(χ^2=0.644,P>0.05).Conclusion Conventional drugs plus tirofiban are effective in the treatment of high-risk non-disabling ischemic progressive stroke.

关 键 词：替罗非班 高危非致残性缺血性进展性卒中患者 神经功能 影响 

分 类 号：R248.1[医药卫生—中医临床基础]